A Phase 2 interventional study of Rimonabant and Placebo in Post-COVID-19 Syndrome, sponsored by Sinfatin S.L. Not yet recruiting at 4 sites in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Sinfatin S.L · Phase 2, Interventional, and Treatment
Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 16th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 13 of the 15 other live ones, and was the 52nd registered.
604 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18–65
Instituto de Investigación Biomédica de Salamanca · Sites in Spain
Ages 18+
Instituto de Investigación Sanitaria Aragón · Sites in Spain
Ages 18+
Universidad Rey Juan Carlos · Sites in Spain
Ages 18+
Hellenic Institute for the Study of Sepsis · Sites in Spain, Germany, Greece and 1 more country
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 146 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (36%) stop at 75 or younger; 15 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 1
First in 2021; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 80 is above the median of 60 across 416 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 60 across the 39 interventional studies, 184 across the 13 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 52 have an industry lead sponsor. The 10 most frequent:
Sinfatin S.L is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Sinfatin S.L has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Post-Acute COVID-19 Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07530757Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition | 2026-11 |
| NCT06928480Instituto de Investigación Sanitaria AragónEffectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19. | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of the study is to assess the effect of rimonabant in cognitive performance in patients with Post-COVID-19 Syndrome, also known as long COVID.
The study will include 80 adults aged 18 to 75 years that will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.
The study will also help to learn about the safety of rimonabant.
RIMOCOVID-1 is a phase IIb proof-of-concept study investigating rimonabant for cognitive impairment associated with post-COVID-19 syndrome. The scientific rationale is based on the hypothesis that altered neuronal excitability contributes to central fatigue and cognitive dysfunction in this population.
Rimonabant is a selective cannabinoid type 1 (CB1) receptor antagonist/inverse agonist. CB1 receptors are involved in neurotransmission and the regulation of neuronal excitability. Neurophysiological research and previous preclinical and clinical studies in other populations provide the rationale for investigating whether CB1 receptor modulation can improve cognitive performance and associated functional limitations in people with post-COVID-19 syndrome.
The selected dose and treatment duration are informed by previous experience with low-dose rimonabant in neurological conditions. The study will evaluate whether this approach produces measurable clinical benefits while characterizing its safety and tolerability in the study population.
Given the psychiatric adverse effects previously associated with rimonabant, the protocol includes targeted screening and ongoing monitoring for depression, anxiety, suicidal ideation, and other changes in mental health. Safety surveillance includes validated questionnaires, clinical assessments, and participant diaries with weekly mood ratings. Predefined criteria guide treatment discontinuation and specialist assessment when indicated.
Participants may continue usual care and rehabilitation in accordance with the protocol's restrictions on concomitant treatments. Assessments after the scheduled end of treatment will evaluate safety and whether any observed clinical changes persist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive rimonabant 5 mg orally once daily for 90 days.
Drug: Rimonabant
Participants receive matching placebo orally once daily for 90 days.
Drug: Placebo
Rimonabant 2.5 mg tablets. Two tablets are taken together orally once a day in fasted conditions, providing a total daily dose of 5 mg. Treatment duration is 90 days.
Placebo tablets matching the appearance of the rimonabant tablets. Two tablets are taken together orally once daily in fasted conditions. Treatment duration is 90 days.
Symbol Digit Modalities Test (SDMT)
The SDMT assesses cognitive processing speed using the validated Spanish version of the test. Participants must match symbols to their corresponding numbers within 90 seconds. The raw score is the number of correct responses, ranging from 0 to 110; higher scores indicate better performance. Age- and education-adjusted scores are calculated using Spanish normative data.
Time frame: Baseline to end of follow-up (day 135)
Fatigue Severity Scale (FSS)
The Fatigue Severity Scale assesses fatigue severity and its impact on daily functioning during the preceding week. It consists of nine items rated from 1 to 7. The mean score ranges from 1 to 7. Higher scores indicate greater fatigue severity.
Time frame: Baseline to end of follow-up (day 135)
Complutense Verbal Learning Test (TAVEC)
The TAVEC assesses verbal learning and episodic memory through repeated word-list learning, interference, delayed recall, and recognition tasks. Age-adjusted standardized scores characterize verbal learning and memory performance.
Time frame: Baseline to end of follow-up (day 135)
Frontal Assessment Battery (FAB)
The Frontal Assessment Battery assesses executive function through six subtests. The total score ranges from 0 to 18. Higher scores indicate better executive functioning.
Time frame: Baseline to end of follow-up (day 135)
Medical Outcomes Study Sleep Scale (MOS-SS)
The MOS Sleep Scale assesses sleep quality and sleep-related problems during the preceding four weeks. Scaled domain scores range from 0 to 100. Higher sleep-problem scores indicate worse sleep, whereas higher sleep-adequacy scores indicate better sleep adequacy.
Time frame: Baseline to end of follow-up (day 135)
Brain Fog Scale
The Brain Fog Scale assesses subjective cognitive symptoms, including mental clouding, slowed thinking, and difficulties with concentration and attention. Higher total scores indicate greater perceived cognitive impairment.
Time frame: Baseline to end of follow-up (day 135)
Sustained Attention to Response Task (SART)
The SART assesses sustained attention and inhibitory control through a computerized go/no-go task. Participants respond to frequent non-target digits and withhold responses to the infrequent target digit 3. Recorded variables include reaction time, commission errors (responses to the target), and omission errors (missed responses to non-targets). Reaction time reflects response speed, while higher error counts indicate poorer sustained attention or inhibitory control.
Time frame: Baseline to end of follow-up (day 135)
Stroop Test
The Stroop Test assesses cognitive inhibition and processing speed through congruent and incongruent conditions. Recorded variables include reaction time and the number of errors in each condition. Longer reaction times indicate slower performance, while higher error counts indicate poorer accuracy.
Time frame: Baseline to end of follow-up (day 135)
Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II assesses depressive symptom severity over the preceding two weeks. It consists of 21 items scored from 0 to 3. The total score ranges from 0 to 63. Higher scores indicate more severe depressive symptoms.
Time frame: Baseline to end of follow-up (day 135)
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale assesses symptoms of anxiety and depression over the preceding week. It consists of 14 items scored from 0 to 3. The combined total score ranges from 0 to 42. Higher scores indicate greater symptom severity.
Time frame: Baseline to end of follow-up (day 135)
Six-Minute Walk Test (6MWT)
The Ten-Meter Walk Test assesses walking performance by measuring the time required to walk 10 meters, expressed in seconds. Shorter completion times indicate faster walking performance.
Time frame: Baseline to end of follow-up (day 135)
Timed Up and Go (TUG) Test
The Timed Up and Go Test assesses functional mobility by measuring the time required to rise from a chair, walk three meters, turn, return to the chair, and sit down. Completion time is expressed in seconds. Shorter times indicate better functional mobility.
Time frame: Baseline to end of follow-up (day 135)
Borg CR10 Scale
The Borg CR10 Scale assesses perceived exertion after the 6MWT. Scores range from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion.
Time frame: Baseline to end of follow-up (day 135)
Patient Global Impression of Change (PGIC)
The Patient Global Impression of Change assesses the participant's overall perception of improvement or worsening compared with their condition at baseline. Participants report whether their overall condition has improved, remained unchanged, or worsened.
Time frame: End of treatment (day 90) and End of follow-up (day 135)
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)
The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels, from no problems to extreme problems or inability to perform the activity. Higher dimension levels indicate greater health problems.
Time frame: Baseline and End of follow-up (day 135)
Overall Mood Scale
The Overall Mood Scale assesses the participant's overall mood using a numerical rating from 0 (very poor mood) to 10 (excellent mood). Participants complete the rating at baseline and weekly in their diary. Higher scores indicate better mood.
Time frame: Baseline to end of follow-up (day 135)
Treatment-Emergent Adverse Events AEs
Safety is assessed by the number of participants experiencing at least one adverse event beginning after the first administration of study medication. Events are classified by severity and relationship to study medication. Serious adverse events, adverse events of special interest, and events leading to withdrawal are summarized separately.
Time frame: First dose of study medication to end of follow-up (day 135)
Visual Analogue Scale (VAS)
The VAS assesses self-perceived health using a 10-cm horizontal line. The left end represents very poor health, and the right end represents very good health. Participants mark the point that best reflects their perceived health status. Positions closer to the right end indicate better perceived health.
Time frame: Baseline to end of follow-up (day 135)
Cognitive Fatigue Rate
Cognitive fatigue is assessed using the Cognitive Fatigue Index derived from the SDMT (CFI-SDMT), which reflects the relative change in correct responses between the initial and final 30-second intervals of the 90-second test. Negative values indicate declining performance. Measures include the CFI-SDMT score and the percentage of participants presenting cognitive fatigue, defined as a decline in performance of more than 10% between these intervals.
Time frame: Baseline to end of follow-up (day 135)
Responder Rates
Responder rates are reported separately as the percentage of participants achieving an increase of at least 4 points in the SDMT total raw score from baseline and the percentage achieving an improvement of at least 10% in the CFI-SDMT from baseline.
Time frame: Baseline to end of follow-up (day 135)
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.
Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 16 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →